A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

NCT02748213 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Xeloda
DRUG: Taxotere
DRUG: Herceptin

Sponsor

Hoffmann-La Roche